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Inhibition of Notch signaling ameliorates insulin resistance in a
FoxO1-dependent manner. Pajvani UB, Shawber CJ, Samuel VT,
Birkenfeld AL, Shulman GI, Kitajewski J, Accili D. Nat Med. July
31, 2011;17(8):961–7. Copyright (2012). Abstract reprinted by
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Abstract. Transcription factor FoxO1 promotes hepatic glucose pro-
duction. Genetic inhibition of FoxO1 function prevents diabetes in
experimental animal models, providing impetus to identify pharma-
cological approaches to modulate this function. Altered Notch signal-
ing is evident in tumorigenesis, and Notch antagonists are in clinical
testing for application in cancer. Here we report that FoxO1 and
Notch coordinately regulate hepatic glucose metabolism. Combined
haploinsufﬁciency of FoxO1 and Notch1 markedly raises insulin sen-
sitivity in diet-induced insulin resistance, as does liver-speciﬁc
knockout of the Notch transcriptional effector Rbp-Jj. Conversely,
Notch1 gain-of-function promotes insulin resistance in a FoxO1-
dependent manner and induces glucose-6-phosphatase expression.
Pharmacological blockade of Notch signaling with c-secretase inhib-
itors raises insulin sensitivity after in vivo administration in lean
mice and in obese, insulin-resistant mice. The data identify a hereto-
fore unknown metabolic function of Notch and suggest that Notch
inhibition is beneﬁcial in diabetes treatment, in part by helping to
offset excessive FoxO1-driven hepatic glucose production.
AND
Insulin regulates liver metabolism in vivo in the absence of
hepatic Akt and Foxo1. Lu M, Wan M, Leavens KF, Chu Q, Monks
BR, Fernandez S, Ahima RS, Ueki K, Kahn CR, Birnbaum MJ. Nat
Med. February 19, 2012;18(3):388–95. Copyright (2012).
Abstract reprinted by permission from McMillan Publishers Ltd.
http://www.ncbi.nlm.nih.gov/pubmed/22344295
Abstract. Considerable data support the idea that forkhead box O1
(Foxo1) drives the liver transcriptional program during fasting and
is then inhibited by thymoma viral proto-oncogene 1 (Akt) after
feeding. Here we show that mice with hepatic deletion of Akt1 and
Akt2 were glucose intolerant, insulin resistant and defective in theirJournal of Hepatology 20
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E-mail address: fanania@emory.edu.transcriptional response to feeding in the liver. These defects were
normalized with concomitant liver-speciﬁc deletion of Foxo1. Nota-
bly, in the absence of both Akt and Foxo1, mice adapted appropri-
ately to both the fasted and fed state, and insulin suppressed
hepatic glucose production normally. A gene expression analysis
revealed that deletion of Akt in liver led to the constitutive activation
of Foxo1-dependent gene expression, but again, concomitant abla-
tion of Foxo1 restored postprandial regulation, preventing the inhibi-
tion of the metabolic response to nutrient intake caused by deletion
of Akt. These results are inconsistent with the canonical model of
hepatic metabolism in which Akt is an obligate intermediate for
proper insulin signaling. Rather, they show that a major role of hepa-
tic Akt is to restrain the activity of Foxo1 and that in the absence of
Foxo1, Akt is largely dispensable for insulin- and nutrient-mediated
hepatic metabolic regulation in vivo. 2012 European Association for the Study of the Liver. Published
by Elsevier B.V.
Today, as I pen this editorial, the Institute of Medicine Com-
mittee on Accelerating Progress in Obesity Prevention of the Uni-
ted States releases a report projecting higher rates of obesity in
children as well as adult men and women in the US in the not
too distant future [1]. The initial text of the ﬁrst of two arti-
cles—both from Nature Medicine—underscores the pressing con-
cerns of the obesity epidemic: ‘‘Type 2 diabetes is associated with
obesity and insulin resistance’’ [2], while the second declares ‘‘In
mammals, the obligate requirement for at least some simple carbo-
hydrate at all times is fulﬁlled during fasting by the liver . . .’’ [3].
As I see it, these articles reﬂect the growing interface between
Endocrinology and Hepatology rooted in modern medical bio-
chemistry, to put an end to insulin resistance.
Both articles focus on FoxO1, the forkhead box-containing
transcription factor that is a downstream target in the insulin sig-
naling pathway. FoxO1, in the presence of normal insulin signal
transduction, is ultimately inactivated just upstream by phos-
phorylated Akt (pAkt). While both molecules are key regulating
proteins in the insulin signal transduction pathway, the bottom
line is, hepatic Akt2 phosphorylation of FoxO1 shuts off FoxO1’s
role in the transcriptional activation of genes associated with glu-
coneogenesis. For different reasons, both reports are explicit that
FoxO1 is a poor target for drug development; and FoxO1 knockout
experiments both in vivo and in vitro in all but rodent models of
insulin resistance (insulin receptor knockout mice) offer surpris-
ingly little improvement in suppressing hepatic glucose output,
i.e., does little to improve insulin resistance [4]. Using different
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Fig. 1. Pathways of hepatic glucose metabolism: old and new. (A) Identity of key players in the hepatocyte insulin signaling pathway. In the fasted state, the forkhead
protein FoxO1 binds the promoters of key genes associated with gluconeogenesis, and glycolysis (phosphoenolpyruvate carboxykinase [PEPCK] and glucose-6-phosphatase
[G6P], respectively. (B) In the fed state, when insulin secretion is increased and glucose is plentiful, the insulin signaling pathway is activated via phosphorylation of the
elements identiﬁed in (A). In the absence of insulin resistance, phosphorylation of FoxO1 heralds an end to its ability to activate transcription of PEPCK, G6P, and other genes
associated with glycogen breakdown and glucose synthesis. (C) The TLKO mice studies by Lu and colleagues strongly contends that another pathway serves to shut off
glucose production even when Foxo1 is not phosphorylated (as is thought to be the case in the insulin resistance state). (D) Pajvani’s group contends, on the other hand, that
the Notch1-Jagged pathway in the state of insulin resistance syndrome activates the downstream transcription factor Rbp-Jk, which either with FoxO1, or independently
can activated G6P and thereby enhance hepatic glucose production. These data imply that Notch1 may be an important target in combating insulin resistance because it is
easier to therapeutically target than FoxO1.
International Hepatologyhypotheses and elegant approaches, both manuscripts provide
intriguing and robust data that upend the insulin signaling path-
way-Akt–FoxO1 axis; and instead provide novel evidence for new
partners that could inhibit transcription of gluconeogenic genes
by FoxO1, under conditions of insulin resistance.
In the manuscript by Pajvani et al. [2], the authors demon-
strate that FoxO1 and the transcription factor Rpb-Jj have a
physical relationship, which activates Notch target genes. One
would not likely make the association between Notch, Jagged,
and the Hes-related families of genes with FoxO1, but in doing
so, Pajavani’s group reasons that there is a mechanistic relation-
ship between the PI3K–Akt–FoxO1 portion of the insulin signal-
ing cascade and the Notch–Rbp-Jj signaling apparatus—a
cascade usually involved in development and neoplasia. As is
standard for Nature papers, there are a plethora of elegant exper-
iments to review; and, it is sometimes difﬁcult to ﬁgure out
whether the mice are on a high fat diet or a standard one.1142 Journal of Hepatology 2012By creating FoxO1+/ and Notch1+/ mice, and cross-breeding
them (FoxO1+/; Notch1+/) the investigators demonstrate there
is stepwise improvement in insulin sensitivity over wild-type
mice (suppressing hepatic glucose production) in both FoxO1+/
and FoxO1+/; Notch1+/ mice; however, insulin sensitivity is
more robust in FoxO1+/; Notch1+/ than in FoxO1+/ alone. The
authors also provide compelling data that Notch1 itself has a crit-
ical role to play, at least in vitro, because Rbp-Jj appears to act as
a transcriptional activator of glucose-6-phophatase, a key
enzyme that initiates glycolysis, in the fasted state, and by
employing gain-of-function studies with respective adenoviral
constructs, both FoxO1 and Notch1 delivery induces glucose-
6-phosphatase without affecting other FoxO1 targets or FoxO1
phosphorylation. Indeed FoxO1+/; Notch1+/ mice show a 35%
decrease in fasting glucose-6-phosphatase expression and a
decrease of nearly 20% of glucose levels. Nonetheless, the authors
make a signiﬁcant case that both FoxO1 and Notch1 play keyvol. 57 j 1141–1143
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roles in the full expression of diet-induced hepatic insulin
resistance.
In the second publication, Lu and colleagues created liver spe-
ciﬁc knockout mice for either Akt-1 or Akt2, or both Akt1 and
Akt2, which were termed DLKO [3]. After initially demonstrating
Akt1 can serve as a ‘proxy’ for hepatic Akt2 in its absence, exper-
iments conducted with standard chow resulted in ‘virtually
undetectable’ phosphorylation of Akt from DLKO livers. Yet, in
spite of the status of this observation, the investigators observed
normal phosphorylation of glycogen synthase kinase 3 (Gsk3a
and Gsk3b). Interestingly, even though FoxO1 is a major target
of activated Akt, and the insulin receptor substrate 2 (Irs2) a
direct Foxo1 target gene [5], the authors found Irs2 to be signiﬁ-
cantly higher in the DLKO mice compared to control mice created
for Akt1 and Akt2. As anticipated, the authors exhaustively dem-
onstrated that the DLKO livers were terribly insulin resistant; but
they reasoned that if a promiscuous FoxO1 was the linchpin for
this problem, ablating it from mouse liver should make things
signiﬁcantly better. Amazingly, the triple liver speciﬁc knockouts
(TLKO, Akt1/Ak2/FoxO1) abolished insulin resistance. In perform-
ing numerous additional experiments, including genome wide
association screening of the DLKO and TLKO mice, the authors
came to the stunning conclusion—which sharply challenges the
prevailing paradigm—that Akt-dependent inhibition of FoxO1
was not the only arbiter of hepatic glucose homeostasis.
Before I get to far aﬁeld from Hepatology, both papers ele-
gantly examine carbohydrate metabolism, but did not study the
lipogenic pathways—also controlled by insulin signal transduc-
tion—and whether or how hepatic triglyceride stores are affected.
Nonetheless, in identifying Notch1 as a regulator of glucose
metabolism in the ﬁrst manuscript, and the second implicating
an insulin-dependent, Akt-independent pathway for suppressing
liver glucose output, the Endocrinologist can go after Notch1 or
another, as yet unidentiﬁed, molecule(s) to reverse hyperglyce-
mia and hepatic insulin resistance in type 2 diabetes mellitus.
Fig. 1 highlights the important lessons to take away from these
two excellent articles. The question for us as Hepatologists, then,
is whether these novel discoveries are equally important inJournal of Hepatology 2012hepatic triglyceride metabolism, because if these ﬁndings are
truly relevant to our patients, we need to prove it and target such
molecules accordingly!Financial support
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